Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study

Barlesi F., Vansteenkiste J., Spigel D., Ishii H., Garassino M., de Marinis F., ...More

LANCET ONCOLOGY, vol.19, no.11, pp.1468-1479, 2018 (SCI-Expanded, Scopus) identifier identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 19 Issue: 11
  • Publication Date: 2018
  • Doi Number: 10.1016/s1470-2045(18)30673-9
  • Journal Name: LANCET ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.1468-1479
  • Istanbul University-Cerrahpasa Affiliated: No

Abstract

Background Antibodies targeting the immune checkpoint molecules PD-1 or PD-L1 have demonstrated clinical efficacy in patients with metastatic non-small-cell lung cancer (NSCLC). In this trial we investigated the efficacy and safety of avelumab, an anti-PD-L1 antibody, in patients with NSCLC who had already received platinum-based therapy.